CU20160005A7 - Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1 h-pirrol-2-il]metilen}-2-0xo-2,3-dihidro-1 h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su procedimiento de preparación, y las formulaciones que la contienen - Google Patents
Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1 h-pirrol-2-il]metilen}-2-0xo-2,3-dihidro-1 h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su procedimiento de preparación, y las formulaciones que la contienenInfo
- Publication number
- CU20160005A7 CU20160005A7 CUP2016000005A CU20160005A CU20160005A7 CU 20160005 A7 CU20160005 A7 CU 20160005A7 CU P2016000005 A CUP2016000005 A CU P2016000005A CU 20160005 A CU20160005 A CU 20160005A CU 20160005 A7 CU20160005 A7 CU 20160005A7
- Authority
- CU
- Cuba
- Prior art keywords
- methylene
- methyl
- thyzolidine
- morfolinilmetil
- pirrol
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 125000001570 methylene group Chemical class [H]C([H])([*:1])[*:2] 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 238000005352 clarification Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Nuevo metanosulfonato de 3-[(3-{ [4-(4-morfolinilmetil)-1H-pirrol-2-il]metilen} -2-oxo-2,3-dihidro-1H-indol-5-il)metil]-1,3-tiazolidina-2,4-diona de fórmula (II) : ESPACIO PARA FÓRMULA que presenta las ventajas siguientes: un procedimiento de obtención simple, reproducible y con un excelente rendimiento. una solubilidad aumentada tanto en agua como en disolventes orgánicos lo que permite considerar extapas de purificaciones tales como clarificaciones, con el fin de aumentar la pureza.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1356870A FR3008411B1 (fr) | 2013-07-12 | 2013-07-12 | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
| PCT/FR2014/051783 WO2015004395A1 (fr) | 2013-07-12 | 2014-07-11 | Nouveau sel de la 3-[(3-{[4-(4-morpholinylméthyl)-1h-pyrrol-2-yl]méthylène}-2-oxo-2,3-dihydro-1h-indol-5-yl)méthyl]-1,3-thiazolidine-2,4-dione, sa préparation, et les formulations qui le contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20160005A7 true CU20160005A7 (es) | 2016-05-30 |
Family
ID=50424327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2016000005A CU20160005A7 (es) | 2013-07-12 | 2016-01-12 | Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1 h-pirrol-2-il]metilen}-2-0xo-2,3-dihidro-1 h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su procedimiento de preparación, y las formulaciones que la contienen |
Country Status (47)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10245270B2 (en) * | 2013-07-12 | 2019-04-02 | Les Laboratoires Servier | Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3663382B2 (ja) * | 2000-02-15 | 2005-06-22 | スージェン・インコーポレーテッド | ピロール置換２−インドリノン蛋白質キナーゼ阻害剤 |
| ATE303998T1 (de) * | 2000-10-17 | 2005-09-15 | Merck & Co Inc | Oral aktive salze mit tyrosinkinaseaktivität |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| EP1458713B1 (en) * | 2001-12-27 | 2005-08-24 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
| RU2006117635A (ru) * | 2003-10-24 | 2007-12-10 | Шеринг Акциенгезельшафт (De) | Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование |
| US7563821B2 (en) | 2005-12-05 | 2009-07-21 | Xenoport, Inc. | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| FR2948940B1 (fr) * | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-12 FR FR1356870A patent/FR3008411B1/fr active Active
-
2014
- 2014-06-26 UY UY0001035629A patent/UY35629A/es unknown
- 2014-06-29 JO JOP/2014/0205A patent/JO3292B1/ar active
- 2014-07-11 GE GEAP201414051A patent/GEP201706712B/en unknown
- 2014-07-11 CN CN201480038854.7A patent/CN105377843B/zh not_active Expired - Fee Related
- 2014-07-11 AU AU2014289059A patent/AU2014289059B2/en not_active Ceased
- 2014-07-11 UA UAA201600944A patent/UA114041C2/uk unknown
- 2014-07-11 WO PCT/FR2014/051783 patent/WO2015004395A1/fr not_active Ceased
- 2014-07-11 US US14/904,260 patent/US9925195B2/en not_active Expired - Fee Related
- 2014-07-11 ME MEP-2017-149A patent/ME02735B/me unknown
- 2014-07-11 CA CA2916380A patent/CA2916380C/fr not_active Expired - Fee Related
- 2014-07-11 PL PL14758600T patent/PL3019497T3/pl unknown
- 2014-07-11 LT LTEP14758600.2T patent/LT3019497T/lt unknown
- 2014-07-11 MY MYPI2016700018A patent/MY183197A/en unknown
- 2014-07-11 HR HRP20171060TT patent/HRP20171060T1/hr unknown
- 2014-07-11 SG SG11201510570YA patent/SG11201510570YA/en unknown
- 2014-07-11 NZ NZ715841A patent/NZ715841A/en not_active IP Right Cessation
- 2014-07-11 MA MA38759A patent/MA38759B1/fr unknown
- 2014-07-11 HK HK16110306.0A patent/HK1222172A1/zh unknown
- 2014-07-11 DK DK14758600.2T patent/DK3019497T3/en active
- 2014-07-11 TW TW105105577A patent/TW201630906A/zh unknown
- 2014-07-11 MX MX2016000332A patent/MX360291B/es active IP Right Grant
- 2014-07-11 RU RU2016104642A patent/RU2680826C9/ru not_active IP Right Cessation
- 2014-07-11 TN TN2015000566A patent/TN2015000566A1/fr unknown
- 2014-07-11 EP EP14758600.2A patent/EP3019497B1/fr active Active
- 2014-07-11 ES ES14758600.2T patent/ES2632570T3/es active Active
- 2014-07-11 AR ARP140102566A patent/AR096882A1/es unknown
- 2014-07-11 TW TW103124019A patent/TWI554510B/zh not_active IP Right Cessation
- 2014-07-11 JP JP2016524879A patent/JP6532459B2/ja not_active Expired - Fee Related
- 2014-07-11 PE PE2015002679A patent/PE20160079A1/es unknown
- 2014-07-11 MD MDA20160003A patent/MD4507C1/ro not_active IP Right Cessation
- 2014-07-11 SI SI201430246A patent/SI3019497T1/sl unknown
- 2014-07-11 RS RS20170461A patent/RS55945B1/sr unknown
- 2014-07-11 KR KR1020167003298A patent/KR20160030399A/ko not_active Ceased
- 2014-07-11 EA EA201600101A patent/EA031526B1/ru not_active IP Right Cessation
- 2014-07-11 HU HUE14758600A patent/HUE032568T2/hu unknown
- 2014-07-11 KR KR1020187006643A patent/KR20180028554A/ko not_active Ceased
- 2014-07-11 AP AP2016008976A patent/AP2016008976A0/xx unknown
- 2014-07-11 PT PT147586002T patent/PT3019497T/pt unknown
-
2016
- 2016-01-04 PH PH12016500017A patent/PH12016500017B1/en unknown
- 2016-01-06 CL CL2016000013A patent/CL2016000013A1/es unknown
- 2016-01-07 DO DO2016000005A patent/DOP2016000005A/es unknown
- 2016-01-07 CR CR20160012A patent/CR20160012A/es unknown
- 2016-01-10 IL IL243526A patent/IL243526B/en not_active IP Right Cessation
- 2016-01-11 NI NI201600009A patent/NI201600009A/es unknown
- 2016-01-11 GT GT201600004A patent/GT201600004A/es unknown
- 2016-01-12 CU CUP2016000005A patent/CU20160005A7/es unknown
- 2016-01-12 SA SA516370388A patent/SA516370388B1/ar unknown
-
2017
- 2017-07-04 CY CY20171100714T patent/CY1119259T1/el unknown
-
2018
- 2018-02-14 US US15/896,273 patent/US20180207171A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| HRP20180450T1 (hr) | Heterobiciklični spojevi kao inhibitori beta-laktamaze | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| BR112016003454A2 (pt) | Uso de composto de metil bardoxolona | |
| CR20140231A (es) | Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih | |
| DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| CR20150447A (es) | Nuevos derivados de pirazol | |
| SV2014004770A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y los composiciones farmacéuticas que los contienen | |
| CL2013003287A1 (es) | Compuestos derivados de 5-trifluorometil-4,5-dihidro-isoxazol; compuestos intermediarios; procedimiento de preparacion; composiciones farmaceuticas que los comprenden; y uso en el tratamiento de una infestacion de parasitos en animales. | |
| EA033811B1 (ru) | Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций | |
| LT3466949T (lt) | Triciklinis junginys kaip priešvėžinis agentas | |
| EP3008044A4 (en) | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors | |
| CR20150250A (es) | Nuevos derivados de piridina | |
| HUE048949T2 (hu) | Algaextraktum immunmoduláló szerként történõ alkalmazásra | |
| CR20140263A (es) | Composicion herbicida que contiene acido de 4-amino-3-cloro-6-(-4-cloro-2-fluor-3-metoxifenil) piridina-2-carboxilico, o los derivados del mismo y fluroxipir, o los derivados del mismo | |
| PT2997033T (pt) | Compostos heterocíclicos tricíclicos fundidos como inibidores de vih integrase | |
| EP2718293A4 (en) | SUBSTITUTED PYRIDOPYRACINES AS NEW SYK-HEMMER | |
| UY35653A (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| DK3360869T3 (da) | Halogen-substitueret heterocyklisk forbindelse anvendelig til behandlingen af sygdomme forårsaget af lpa. | |
| CO6852077A2 (es) | Composiciónes que comprenden ditiínas sustituidas fungicidas y compuestos activos adicionales | |
| EA201500931A1 (ru) | Производные пиридин-4-ила | |
| CR20150511A (es) | Nuevos derivados de purina | |
| AR092971A1 (es) | Inhibidores de agrecanasa | |
| EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
| CR20130375A (es) | Preparaciones que contienen antraquinona/formulaciones de lignina |